loading...| Preferred Name |
Gefitinib |
|
| Synonyms |
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine GEFITINIB Gefitinib Iressa ZD 1839 ZD1839 gefitinib |
|
| Definitions |
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1855 |
|
| Accepted_Therapeutic_Use_For |
Non-Small Cell Lung Carcinoma |
|
| ALT_DEFINITION |
A drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. |
|
| CAS_Registry |
184475-35-2 |
|
| CHEBI_ID |
CHEBI:49668 |
|
| Chemical_Formula |
C22H24ClFN4O3 |
|
| code |
C1855 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04) |
|
| Display_Name |
Gefitinib |
|
| FDA_UNII_Code |
S65743JHBS |
|
| FULL_SYN |
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine GEFITINIB Gefitinib Iressa ZD 1839 ZD1839 gefitinib |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Gefitinib |
|
| Legacy Concept Name |
Gefitinib |
|
| Maps_To |
Gefitinib |
|
| NCI_Drug_Dictionary_ID |
43649 |
|
| NSC Number |
715055 |
|
| PDQ_Closed_Trial_Search_ID |
43649 |
|
| PDQ_Open_Trial_Search_ID |
43649 |
|
| Preferred_Name |
Gefitinib |
|
| prefixIRI |
Thesaurus:C1855 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C1122962 |
|
| subClassOf |